Фенотипирование рака молочной железы. Современные алгоритмы лечения и диагностики метастатического рака молочной железы

Хасанова Альфия Ирековна, Хусаинова Гульнара Наилевна, Гатауллин Ильгиз Габдуллович et al. · Medical Almanac · 2010

Decision making on systemic treatment of women with metastatic breast cancer is based on features like estrogen receptor (ER), progesterone receptor (PgR), and HER2 status assessed on the primary tumor. We evaluated the concordance of receptor status between primary tumor and liver metastases (mts), lung metastases, limph.nodules metastases and mts in adnexis its impact on treatment choice. We retrospectively and prospectively analyzed pacients a performed from 1998 to 2010. All tissue samples, both from primary tumor and liver, lung, nodules and adnexx mts, were analyzed for ER, PgR and HER2 status. Changes in ER status were observed in 29,5%. Changes in PgR status were observed in 25,8%.Changes in HER2 status were observed in 26%. There was a discordance in receptor status, and HER 2 status between primary tumor and mts, which led to change in therapy

Cited by 0 works.

Authors